erlotinib hydrochloride has been researched along with homoharringtonine in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (homoharringtonine) | Trials (homoharringtonine) | Recent Studies (post-2010) (homoharringtonine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 501 | 53 | 255 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sarwar, A; Su, Q; Tang, W; Tang, X; Yang, T; Zhang, Y; Zhu, M; Zhu, Z | 1 |
1 other study(ies) available for erlotinib hydrochloride and homoharringtonine
| Article | Year |
|---|---|
Homoharringtonine sensitizes pancreatic cancer to erlotinib by direct targeting and miRNA-130b-3p-mediated EphB4-JAK2-STAT3 axis.
Topics: Cell Line, Tumor; Cell Proliferation; Erlotinib Hydrochloride; Homoharringtonine; Humans; Janus Kinase 2; MicroRNAs; Pancreatic Neoplasms; STAT3 Transcription Factor | 2023 |